In an open-label RCT of 390 men with osteoporosis or osteopenia, 12 months of denosumab, alendronate or zoledronic acid increased spine and hip BMD and TBS with no significant differences between drugs; zoledronic acid had more adverse events.
RCTn = 390
Zhou et al. Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis